News
Phase 3 trial of an autologous cell therapy for COPD registered at a Guangzhou hospital
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
A study registered on ClinicalTrials.gov and last updated on 24 September 2026 plans to test an autologous cell therapy, REGEND001, made from airway basal stem cells, in about 102 adults with chronic obstructive pulmonary disease and emphysema. The record describes a multicentre, randomised, blinded, placebo-controlled phase 3 trial at The First Affiliated Hospital of Guangzhou Medical University in Guangzhou, names Regend Therapeutics as the sponsor, shows the record first posted on 18 September 2026, and gives the status as not yet recruiting. Registry entries describe studies; they are not recommendations.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — open access / public domain; summary and link published here, the original remains authoritative.